taug_logo_f_improf_179x131Tauriga Sciences, Inc is a diversified biotechnology company that entered the marijuana industry this year. It made its entry by acquiring the medical cannabis manufacturer Honeywood LLC, which became one of Tauriga’s subsidiary companies.

Tauriga was founded in 2001 and has since gone through different businesses and names. Among these are New England Acquisitions, Atlantic Wine Agencies, and Novo Energies Corp. It finally became Tauriga Sciences, Inc in 2013.

Today, Tauriga Sciences, Inc is traded in OTC markets under the symbol TAUG. Its market cap is pegged at USD 14.6 M.

The company takes on the strategy of diversifying its portfolio through the acquisition of licenses, exclusive and non-exclusive rights, as well as entire businesses. Currently, Tauriga’s featured subsidiary companies are Microbial Robotics LLC (previously known as Bacterial Robotics LLC), Pilus Energy LLC, and on the marijuana front, Honeywood LLC.

Microbial Robotics LLC is a firm that bio-engineers certain micro-organisms to ‘program’ them into microscopic robots. Such micro robots are deemed useful in various applications including disease reduction, water cleaning, food cultivation, fuel production, and therapeutics production.

Pilus Energy is a subsidiary of Microbial Robotics and it has also been acquired by Tauriga Sciences. It is also a biotech firm, with a specialty in genetically engineering certain bacteria. The bacteria process wastewater to produce direct current electricity and several useful gases and chemicals.

Lastly, Tauriga’s subsidiary in the medical cannabis space, which it acquired in March 2014, is Honeywood LLC. This subsidiary develops and sells topical cannabis products such as healing creams and skin lotions. It sells these products through online channels under the Doc Greens brand.

At the helm of Tauriga Sciences is Dr. Stella Sung, the company’s CEO, Chairman, COO, and Interim CFO. With her are VP for Strategic Planning Seth M. Shaw, Chief Medical Officer Dr. Lawrence A. May, and Operations Manager Ghalia Lahlou. Other executives include the VP and General Manager of Pilus Energy Ian Harrison, and VP of NuclearBot Development David Schweizer.


Yahoo! Finance: TAUG News

Latest Financial News for TAUG

Tauriga Sciences Inc. Confirms Substantial Pre-Orders for its 25mg CBD & CBG Infused Tauri-Gum

Tauriga 04-14-2021 Pomegranate Blister Pack Design: 25mg CBD Tauri-Gum™ NEW YORK, NY, April 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has received substantial Pre-Orders for its new, 25mg CBD & CBG infused Tauri-Gum™ versions. The enhanced 25mg CBD & CBG infusion concentrations apply to five distinct Tauri-Gum™ SKUs: Mint (CBD), Blood Orange (CBD), Pomegranate (CBD), Peach-Lemon (CBG), and Black Currant (CBG). CBD = CANNABIDIOL CBG = CANNABIGEROL The Company has made the following strategic decision: There will be No Increase in Tauri-Gum™ Retail Prices (“MSRP”). The Company has been successful in reducing costs (basic factors of production costs), pursuant to the Tauri-Gum™ manufacturing process. Lastly, the Company has generated strong E-Commerce sales during the first two weeks of April 2021. Between the Pre-Orders (25mg Tauri-Gum™) and its strong E-Commerce sales, the Company is confident in its growth prospects for Fiscal Year 2022 (Period: April 1, 2021 – March 31, 2022). ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc.4 Nancy Court, Suite 4Wappingers Falls, NY 12590Chief Executive OfficerMr. Seth M. ShawEmail: sshaw@tauriga.comcell # (917) 796 9926Company Instagram: @taurigumPersonal Instagram: @sethsms47Twitter: @SethMShawCorp. Website: www.tauriga.comE-Commerce Website: www.taurigum.com Attachment Tauriga 04-14-2021

Tauriga Sciences Inc. to Launch Non-Fungible Tokens (NFTs) Creation & Content Division, as Part of its Long-Term Branding, Marketing, and Monetization Strategies

04_13_2021 PR Image An Example of NFT Tauri-Gum™ Art Content The Company’s Newly Formed Division Will be Called: NFTauriga Corp. NEW YORK, NY, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced the establishment of a Non-Fungible Tokens (“NFTs”) content division, as part of the Company’s long-term Tauri-Gum™ branding and marketing strategies. The Company will work closely with its existing partners and relationships, in creating unique, innovative, and valuable content. The Company will retain full ownership rights to any and all cryptographic assets that it creates, however may enter into revenue sharing agreements to both enhance its content and support important social causes. NFTs, or non-fungible tokens, are a type of digital asset where ownership is recorded on a digital ledger blockchain. Each NFT is unique and can be viewed as a collectible that cannot be duplicated, making them singular and potentially valuable. NFTs can represent digital files, such as art, audio, videos, posters, album art and other forms of creative work. The Company believes that there is significant potential value in building an infrastructure to support these new forms of digital assets from a marketing, promotional, branding, and monetization perspective. The successful launch of NFTs can help the company with web traffic conversion, revenue streams, mission critical marketing, product promotions, and the support of important social causes. The Company will continually update its shareholders, as progress is realized – with respect to this NFT initiative. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment 04_13_2021 PR Image

Tauriga Sciences, Inc. Invited to Present at SEQUIRE 2021 Cannabis Conference on April 20th, 2021

The Company’s Virtual Presentation is Scheduled at 1:00 pm – 1:25 pm EST on April 20th, 2021 NEW YORK, NY, April 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has been invited to Present at the SEQUIRE 2021 Cannabis Conference (the “Conference”) on April 20th, 2021. The Company’s Corporate Presentation is scheduled at 1:00 pm – 1:25 pm EST. Tauriga Sciences Inc.’s CEO, Seth M. Shaw, will deliver the Company’s Presentation. The SEQUIRE platform, owned by SRAX, Inc., has more than 3,000,000 retail investors. The 2021 SEQUIRE Cannabis Conference:Conference Link: https://cannabis-conference.mysequire.com ABOUT TAURIGA SCIENCES, INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com. Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020, the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc.4 Nancy Court, Suite 4Wappingers Falls, NY 12590Chief Executive OfficerMr. Seth M. ShawEmail: sshaw@tauriga.comCell # (917) 796 9926Company Instagram: @taurigumPersonal Instagram: @sethsms47Twitter: @SethMShawCorp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com

Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both Revenue Generated [$10,000+] and Number of Individual Transactions [207]

These E-Commerce Records Were Achieved on the Date: Monday – April 5, 2021 NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today reported record daily results, with respect to its highest margin E-Commerce business segment. On Monday, April 5, 2021, the Company generated $10,000+ in Daily E-Commerce Sales and recorded 207 individual E-Commerce Order Transactions. As of 8:00am EST this morning, the Company has received Approximately 5,900 E-Commerce Orders. In other news, the Company has completed payment for the initial production run of its Delta-8-Tetrahydrocannabinol (“Delta-8-THC” or “Delta-8”) infused version of Tauri-Gum (9th Overall Tauri-Gum™ SKU). This product is being manufactured in Evergreen Mint flavor with an MSRP of $18.99 per Blister Pack. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com

Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic, Hebrew, Dutch, Spanish, Polish, French, German, Italian, Finnish, and Turkish

04_01_2021 Afternoon PR Image Tauri-Gum™ Blister Pack Translated into Polish The Company is Focused on the International Expansion of Its Flagship Brand Tauri-Gum™ NEW YORK, NY, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has completed the translated versions of its Tauri-Gum™ blister pack (packaging) into the following twelve languages: Mandarin Chinese, Japanese, Arabic, Hebrew, Dutch, Spanish, Polish, French, German, Italian, Finnish, and Turkish. The Company is focused on the international expansion of its flagship Tauri-Gum™ brand, which has recently been enhanced to 25mg infusion concentration(s) for its CBD & CBG products. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. There can be no guarantee that the Company will generate any future revenue, from bidding on U.S. Government contract(s). Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment 04_01_2021 Afternoon PR Image